



International Prostate Cancer Symposium
Where translational research meets therapeutic innovation

IPCS 2026

Detailed Programme

28-29 April 2026
Palazzo dei Congressi, Lugano, Switzerland

 www.apccc.org/ipcs

The program may slightly change

IPCS 2026 is organised by the Foundation for the Institute of Oncology Research (IOR) in collaboration with APC Society, with the support of

AAGR American Association
for Cancer Research®
FINDING CURES TOGETHER™

EAU European
Association
of Urology

Tuesday April 28



All sessions take place in Room A

14:00 – 14:10

WELCOME and OPENING REMARKS

14:10 – 14:50

AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) OPENING LECTURE

Targeting AR: Opportunities and Drawbacks



C. Sawyers

Chair of the human oncology and pathogenesis program,
Memorial Sloan Kettering Cancer Center, USA

SESSION 1

NEXT-GENERATION AR INHIBITORS: DEGRADERS & BEYOND

Chaired by **J.P. Theurillat**, Institute of Oncology Research, CH
A.J. Armstrong, Duke University School of Medicine, USA

14:50 – 15:10

Targeted protein degradation for regulation of nuclear hormone receptors



N.H. Thomä

EPFL, CH

15:10 – 15:30

Preventing Disease Progression under AR suppression Through TRIM24 Degradation



J.P. Theurillat

Institute of Oncology Research (IOR), CH

15:30 – 15:50

Lessons from clinical trials involving AR degraders



A.J. Armstrong

Duke University School of Medicine, USA

15:50 – 16:10

2 Selected Abstract: Novel treatment approaches

16:10 – 16:40

Coffee break

SESSION 2

COMBINATION THERAPIES: HOW TO PREVENT ARI RESISTANCE

Chaired by **M. Rubin**, University of Bern, CH
A. Briganti, Vita-Salute San Raffaele University, IT
J. Walz, Institut Paoli-Calmettes Cancer Centre, FR

16:40 – 17:00

Targeting heterogeneity in metastatic prostate cancer to prevent resistance



P.S. Nelson

Vice President of Precision Oncology Fred Hutch,
Fred Hutchinson Cancer Center, USA

17:00 – 17:20

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance



W. Zwart

Chair of the NKI Translational Research Board,
Netherlands Cancer Institute, NL

17:20 – 17:40

How to prevent ARPi resistance in the neo-adjuvant setting



M.E. Taplin

Dana-Farber Cancer Institute, USA

17:40 – 18:00

2 Selected Abstract: Therapeutic resistance

Wednesday April 29



09:00 – 09:40

KEYNOTE LECTURE

Liquid Biopsies: Methods and Applications



F. Demichelis

Vice-Rector for research of the University of Trento, IT

SESSION 3

PREDICTIVE BIOMARKERS: CAN WE DISCERN SIGNAL FROM NOISE?

Chaired by H. Beltran, Dana-Farber Cancer Institute, USA
H. Scher, Memorial Sloan Kettering Cancer Center, USA
A. Bjartell, Lund University, SE

09:40 – 10:00

Detection of Neuroendocrine Prostate Cancer via DNA Methylation



H. Beltran

Dana-Farber Cancer Institute, USA

10:00 – 10:20

Molecular sub-grouping of metastatic hormone-sensitive prostate cancer



G. Attard

University College London, UK

10:20 – 10:50

Coffee break

10:50 – 11:10

Predictive markers for metastatic hormone-sensitive prostate cancer



C. Sweeney

Director of the South Australian Immunogenomics Cancer Institute, University of Adelaide, AU

11:10 – 11:30

EUROPEAN ASSOCIATION OF UROLOGY (EAU) LECTURE

Adjunct Secretary General, European Association of Urology
University of Tuebingen Medical School, DE
Chaired by **A. Stenzl**, Director of the Department of Urology,

Neoadjuvant therapy in prostate cancer: present and future directions



A. Briganti

Vita-Salute San Raffaele University, IT

SESSION 4

NEW FRONTIERS IN IMMUNOTHERAPY PROSTATE CANCER?

Chaired by **J. de Bono**, The Institute of Cancer Research, UK
C. Drake, VP Immuno-Oncology, Janssen, USA

11:30 – 11:50

Immune response patterns in prostate cancer



A. Alimonti

Director of the Institute of Oncology Research (IOR), CH

11:50 – 12:10

Novel T-cells engagers in prostate cancer



J. de Bono

Director of the Drug Development Unit, The Institute of Cancer Research, UK

12:10 – 12:30

Next-generation approaches to immunotherapy



C. Drake

Adjunct Professor of Medicine and Urology, Columbia University Herbert Irving Comprehensive Cancer Center, USA

12:30 – 14:00

POSTER Lunch break and **POSTER SESSION**
13:30-13:50 **POSTER FLASH** 10 Selected Abstract*

14:00 – 14:40

KEYNOTE LECTURE

Radioligand Therapies: How to improve outcomes?



M. Hofman

Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, AU

SESSION 5

THERANOSTICS FOR TARGETED THERAPY IN PROSTATE CANCER

Chaired by **M. Hofman**, Peter MacCallum Cancer Centre, AU
L. Emmett, St Vincent's Hospital Sydney, AU

14:40 – 15:00

Next-Generation Radiopharmaceuticals: What's on the Horizon?



K. Herrmann

Chair of the Department of Nuclear Medicine, University Hospital Essen, DE

15:00 – 15:20

Lu-PSMA to treat metastatic castration-resistance prostate cancer



L. Emmett

Director of Theranostics and Nuclear medicine, St Vincent's Hospital Sydney, AU

15:20 – 15:40

2 Selected Abstract: *Theranostics*

15:40 – 16:10

Coffee break

SESSION 6

EMERGING ANTIBODY-DRUG CONJUGATES

Chaired by **T. Powles**, University of London, UK

E. Antonarakis, University of Minnesota, USA

G. Curigliano, European Institute of Oncology, IT

16:10 – 16:30

B7-H3 as an actionable therapeutic target



E. Antonarakis

Associate Director in Translation Research Masonic Cancer Center, University of Minnesota, USA

16:30 – 16:50

Innovative payloads for ADCs in cancer treatment



T. Powles

Director of Barts Cancer Centre, University of London, UK

16:50 – 17:10

2 Selected Abstract: *Emerging antibody-drug conjugates*

17:10 – 17:25

CLOSING REMARKS

***selected abstracts categories:**

- Molecular biology and genetics
- Novel treatment approaches (immunotherapy, radioligands, etc.)
- Therapeutic resistance
- Diagnostics and biomarkers
- Theranostics
- Emerging antibody-drug conjugates
- Phase 0/1/2 clinical trials